文献速递临床试验与 GCP

澳大利亚恶性胸腔积液(AMPLE)-4试验:局部抗生素预防留置胸膜导管感染的多中心随机试验研究方案

Australasian Malignant PLeural Effusion (AMPLE)-4 trial: study protocol for a multi-centre randomised trial of topical antibiotics prophylaxis for infections of indwelling pleural catheters.
PubMed 文献 · Trials · 2024-04-10

澳大利亚恶性胸腔积液(AMPLE)-4试验是一项实用性、多中心、开放标签、随机试验,计划招募最多418例接受留置胸膜导管(IPC)的恶性胸腔积液患者,1:1随机分配至定期局部莫匹罗星预防组或不使用莫匹罗星(标准治疗)组。主要结局为导管插入至随访结束期间发生IPC相关(胸膜、皮肤或隧道)感染的患者百分比,随访最长6个月。

要点

  • 接受IPC的恶性胸腔积液患者随机分为局部莫匹罗星预防组与标准治疗组。
  • 干预组每次引流后在IPC出口处局部涂抹莫匹罗星,每周至少两次。
  • 主要结局为导管插入至随访结束期间IPC相关感染的患者百分比,随访最长6个月。

核心结论

  • 该试验结果将确定莫匹罗星预防对需要IPC的恶性胸腔积液患者的疗效。
  • 该试验将提供IPC相关感染的发生率、微生物学及潜在感染途径数据。

研究设计与样本

  • 实用性、多中心、开放标签、随机试验。
  • 符合条件的恶性胸腔积液并留置IPC的患者按1:1随机分配至定期局部莫匹罗星预防组或不使用莫匹罗星(标准治疗)组。
  • 根据中期分析结果,试验将招募最多418名参与者。
  • 每周通过电话或面对面进行随访,最长6个月。

主要发现

  • 主要结局为导管插入至随访结束期间发生IPC相关(胸膜、皮肤或隧道)感染的患者百分比。
  • 次要结局包括感染分析(类型和发作次数)、住院天数、卫生经济学、不良事件和生存。

关键数值与推荐

  • 干预组在每次引流后在IPC出口处局部涂抹莫匹罗星,每周至少两次。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Malignant pleural effusion (MPE) is a debilitating condition as it commonly causes disabling breathlessness and impairs quality of life (QoL). Indwelling pleural catheter (IPC) offers an effective alternative for the management of MPE. However, IPC-related infections remain a significant concern and there are currently no long-term strategies for their prevention. The Australasian Malignant PLeural Effusion (AMPLE)-4 trial is a multicentre randomised trial that evaluates the use of topical mupirocin prophylaxis (vs no mupirocin) to reduce catheter-related infections in patients with MPE treated with an IPC. METHODS: A pragmatic, multi-centre, open-labelled, randomised trial. Eligible patients with MPE and an IPC will be randomised 1:1 to either regular topical mupirocin prophylaxis or no mupirocin (standard care). For the interventional arm, topical mupirocin will be applied around the IPC exit-site after each drainage, at least twice weekly. Weekly follow-up via phone calls or in person will be conducted for up to 6 months. The primary outcome is the percentage of patients who develop an IPC-related (pleural, skin, or tract) infection between the time of catheter insertion and end of follow-up period. Secondary outcomes include analyses of infection (types and episodes), hospitalisation days, health economics, adverse events, and survival. Subject to interim analyses, the trial will recruit up to 418 participants. DISCUSSION: Results from this trial will determine the efficacy of mupirocin prophylaxis in patients who require IPC for MPE. It will provide data on infection rates, microbiology, and potentially infection pathways associated with IPC-related infections. ETHICS AND DISSEMINATION: Sir Charles Gairdner and Osborne Park Health Care Group Human Research Ethics Committee has approved the study (RGS0000005920). Results will be published in peer-reviewed journals and presented at scientific conferences. TRIAL REGISTRATION: Australia New Zealand Clinical Trial Registry ACTRN12623000253606. Registered on 9 March 2023.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Lau EPM, Ing M, Vekaria S, et al. Australasian Malignant PLeural Effusion (AMPLE)-4 trial: study protocol for a multi-centre randomised trial of topical antibiotics prophylaxis for infections of indwelling pleural catheters. Trials. 2024. PMID: 38594766. doi:10.1186/s13063-024-08065-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。